Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Gross margin57.2%+3.2pp55.4%+0.3pp54.5%+0.5pp53.9%53.9%
Operating margin-70.1%+7.8pp-71.5%-2.0pp-77.4%+8.9pp-80.1%-78%
Net margin-60.3%+41.4pp-73%+11.1pp-87.9%+12.1pp-94%-101.6%
EBITDA margin-68.4%+7.8pp-69.9%-2.2pp-76%+7.8pp-78.6%-76.3%
Free cash flow margin-55.4%+29.7pp-56.1%+23.3pp-68.3%+26.1pp-79.5%-85.1%
Efficiency
Inventory turnover2.4×-1.2×2.6×-1.5×3.3×3.4×3.5×
Liquidity
Current ratio10.7×8.7×10.6×
Quick ratio9.7×9.8×
Cash ratio1.3×1.5×
Leverage
Debt-to-equity
Debt-to-assets
Per Share
Book value per share$6.10-40.2%$7.10+118%$6.76+120%$6.95$10.22
Valuation
Market capitalization$708.98M-8.6%
Enterprise value$685.68M
Price / sales6.4×
Price / book2.6×
EV / sales6.2×
Free cash flow yield-8.6%
Earnings yield-9.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Beta Bionics, Inc. Common Stock's profit margins?
Beta Bionics, Inc. Common Stock (BBNX) runs a 57.2% gross margin and a -70.1% operating margin, with a -60.3% net margin.
Where do Beta Bionics, Inc. Common Stock's ratios come from?
Every ratio is computed from Beta Bionics, Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.